系统性红斑狼疮诊断标准及治疗进展

Progresof diagnosticriteriand treatmenin systemilupuerythematosus

系统性红斑狼疮（SLE）是一种常见的、复杂的自身免疫性疾病，2009年美国风湿病学会（ACR）年会上SLE国际临床协作组提出新的SLE分类标准，分为临床标准和免疫学标准2个部分，更强调临床相关性，更重视脏器受累，灵敏度更高，但特异性低于1997年ACR标准。KidneyDisease：ImprovingGlobalOutcomes（KDIGO）指南和ACR指南分别对狼疮性。肾炎的治疗原则加以阐述，建议儿童和成人的治疗方案一样，根据体型和肾小球滤过率调整剂量。生物制剂可用于传统免疫抑制剂无效或不能耐受的SLE，是SLE治疗革命性的进展。

Systemilupuerythematosu（SLE） icommon and complicated autoimmune disease. The Sys- temiLupuInternational Collaborating ClinicGroup undertook revision of the American College of Rheumatology （ACR） classification criterifoSLE in 2009. The new revision included clinical criteriand immunogicriteria, and had greatesensitivity bulowespecificity than AC- 1997. Kidney Disease：Improving Global Outcome（KDIGO） clinical practice guideline and ACguideline elaborated the treatmenfolupunephritis. Children with lupunephritishould receive the same therapieaadultwith dosing based on patiensize and glomerulafiltration rate. Biological agentcould be used to trearefractory SLE othose who were intoleranto traditional immunosuppressant.